Read-Gene S.A. (WSE:RDG)

Market Cap	49.52M
Revenue (ttm)	12.67M
Net Income (ttm)	-455.44K
Shares Out	11.79M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,652
Average Volume	507
Open	4.540
Previous Close	4.340
Day's Range	4.020 - 4.600
52-Week Range	4.000 - 6.660
Beta	-1.00
RSI	36.46
Earnings Date	Feb 10, 2025

About Read-Gene

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. Chemoprevention is the use of natural or synthetic substances to stop, reverse, or delay the process of developing cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic-oncological consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. Read-Gene S....

• Industry: Biotechnology & Medical Research
• Sector: Healthcare
• Founded: 2005
• Employees: 29
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RDG